Syndax, a biopharmaceutical company focusing on cancer therapies, has announced the pricing of a $150 million public offering of common stock.
The offering price is $22 for each share of 6,818,182 shares of stock. Additionally, the company granted underwriters a 30-day option to purchase up to an additional 1,022,727 shares of common stock, according to a Dec. 7 Syndax news release provided to Becker's.
The offering is expected to formally close Dec. 9.